KOSDAQBatteries489500

LK Chem

₩19,670▲ 1.03%2026-11-18 close
Market Cap
₩125.9B
Turnover
₩100M
Volume
7.5K
Shares out.
6.4M
PER
24.4×
PBR
2.0×
EPS
₩826
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Recovery on DIS volumes; new materials are the test

LK Chem's revenue and operating profit have risen for three straight quarters since the 4Q 2025 low, but parent-company net profit fell sharply in 3Q 2026, so the durability of the recovery is still being tested.

  1. 1

    Disclosed 2025 results show revenue of KRW 20.2 billion and operating profit of KRW 4.57 billion, both down from 2024, with operating margin falling to 22.6%.

  2. 2

    Revenue and operating profit rose for three consecutive quarters from 1Q 2026 through 3Q 2026, reaching KRW 7.87 billion and KRW 1.99 billion respectively in 3Q 2026.

  3. 3

    Parent-company net profit fell to KRW 709 million in 3Q 2026, down 62.0% quarter on quarter, moving in the opposite direction to operating profit.

  4. 4

    A DIS supply contract worth about KRW 21.2 billion, signed in May 2026, has been feeding into results since 2Q 2026 and runs until April 30, 2027.

  5. 5

    Domestic hafnium precursors and perovskite materials are presented as medium-term options, and the company expects perovskite R&D to be completed in 2028.

02

Business structure

LK Chem, founded in November 2007, is a semiconductor materials company that develops and mass-produces ligands and precursors used in atomic layer deposition (ALD) processes.

Although the sector classification is secondary batteries, its actual business is concentrated in semiconductor deposition materials, so its demand drivers are only loosely linked to the battery sector.

Its core products are CP and PCP ligands used for DRAM insulating films and DIS precursors used for nitride film deposition in system semiconductor and 3D NAND processes. The company has said it was the first in the world to commercially produce PCP ligands and the first in Korea to mass-produce DIS precursors.

High-k product lines such as molybdenum precursors and yttrium ligands are increasing their share of revenue. For hafnium-based precursors, the key raw material HfCl4 has been imported in full, and the company is pursuing whole-process localization.

Its No. 2 plant is operating, and a third plant in Dangjin, South Chungcheong Province, is being planned. The DIS supply contract signed in May 2026 was reported as an annual contract with U-Pi Chemical.

Its differentiators include a research workforce in which 77% hold master's or doctoral degrees, proprietary process patents, and ultra-high-purity refining technology. However, at the time of its 2025 listing, about 90% of revenue was concentrated in a single customer, which was classified as a risk.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩5.6B₩1.6B28.0%
2025Q4₩5.5B₩800M14.4%
2026Q1₩6.1B₩1.1B18.3%
2026Q2₩7.6B₩1.9B24.9%
2026Q3₩7.9B₩2B25.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2023₩15.3B₩5.6B₩3.4B36.8%28.9%178.9%
2024₩25B₩10.1B₩6.8B40.5%19.9%19.7%
2025₩20.2B₩4.6B₩4.4B22.6%7.3%11.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On an annual basis, LK Chem's results peaked in 2024. Revenue rose 64.2% from KRW 15.3 billion in 2023 to KRW 25 billion in 2024, and operating profit rose 80.7% from KRW 5.61 billion to KRW 10.1 billion. 2024 was the largest year of 2023 to 2025 for revenue, operating profit and parent-company net profit.

In 2025, revenue fell 19.4% to KRW 20.2 billion, operating profit fell 54.9% to KRW 4.57 billion, and parent-company net profit fell 36.5% to KRW 4.35 billion.

The main causes the company gave in its disclosure were lower volumes of High-k materials, lower selling prices for key products, and higher headcount and fixed costs after the completion of the No. 2 plant expansion. Reports also said that higher R&D spending, which was expensed, weighed on profitability.

Operating margin was 36.8% in 2023 and 40.5% in 2024 before falling to 22.6% in 2025. Total equity at the end of 2025 was KRW 59.6 billion and total liabilities were KRW 6.53 billion, with the debt ratio falling from 178.9% in 2023 to 11.0% in 2025.

Operating cash flow was KRW 4.84 billion in 2023, KRW 10.3 billion in 2024 and KRW 4.61 billion in 2025. On a quarterly basis, the low point was 4Q 2025, with revenue of KRW 5.49 billion and operating profit of KRW 789 million.

Revenue then rose to KRW 6.06 billion in 1Q 2026, KRW 7.64 billion in 2Q 2026 and KRW 7.87 billion in 3Q 2026. Operating profit was KRW 1.11 billion, KRW 1.9 billion and KRW 1.99 billion over the same three quarters.

However, parent-company net profit fell 62.0% quarter on quarter to KRW 709 million in 3Q 2026, so higher operating profit did not carry through to bottom-line profit that quarter. Parent-company net profit summed to KRW 5.22 billion over the last four quarters.

05

Industry analysis

The market LK Chem serves is the area of advanced semiconductor scaling where atomic layer deposition (ALD) is used. In its 1Q 2026 results coverage, the company said that expanding semiconductor miniaturization processes increased supply of ALD precursors and high-value materials.

Its core DIS precursor is classified as a low-k material used in deposition processes for system semiconductors and 3D NAND flash. In the high-k segment, hafnium materials are cited as a key raw material for advanced chips.

Hafnium-based precursor feedstock has been fully imported, and the company is pursuing localization. In a report published after May 2026, NH Investment & Securities pointed to whole-process localization of hafnium-based precursors, whose patents expire at the end of this year.

The same report mentioned expectations for expanded supply of DIS precursors to customers in Taiwan and mainland China. On competition, the company cites its proprietary process patents and refining technology as differentiators.

On the other hand, the concentration of about 90% of revenue in a single customer was classified as a risk at the time of listing. Compared with cathode and electrolyte makers in the secondary battery sector, its demand comes from semiconductor fabrication, so its cycle exposure works differently.

06

Outlook

The first pillar the company points to with a confirmed timeline is the DIS supply contract. The annual contract of about KRW 21.2 billion signed in May 2026 runs from May 14, 2026 to April 30, 2027.

Based on this contract, the company says it is raising utilization of new precursors at its No. 2 plant, and it is also pursuing infrastructure expansion at the No. 2 plant and securing land for a No. 3 plant.

The Dangjin No. 3 plant is intended as a base to expand medium-term production capacity and mass-produce new materials. According to a securities report, the Dangjin No. 3 plant is expected to host hafnium material production processes and dedicated perovskite production equipment.

NH Investment & Securities, in a report published after May 2026, projected 2026 revenue of KRW 33.4 billion, up 65.6% from the prior year, and operating profit of KRW 11 billion, up 141.0%.

Against that estimate, cumulative operating profit through 3Q 2026 is about KRW 5 billion, so the profit trajectory in 4Q and beyond is the key variable. Medium-term options include hafnium localization and perovskite materials.

The company has signed a technology transfer contract with the Korea Research Institute of Chemical Technology for silicon-perovskite tandem solar cell materials. A 2026 media report pointed to 3Q 2027 as the target for completing investment including the Dangjin No. 3 plant.

The points to check are whether localized hafnium products enter mass production after the patent expires at the end of 2026, and whether a follow-on contract continues after the DIS contract ends in April 2027.

07

Valuation

PER
24.4×
PBR
2.0×
ROE
8.5%
EPS
₩826
BPS
₩10,197
Dividend per share
₩0

The valuation discussion here looks only at how the share price relates to earnings and book value. The price-to-book ratio sits in a range with a premium over net asset value, and with equity of KRW 59.6 billion, the premium is viewed by some as reflecting expectations for new materials and expanded DIS supply.

A 2026 media report said enthusiasm for new materials pushed the share price above its IPO price. On the last four quarters of parent-company net profit, which totaled KRW 5.22 billion, the price-to-earnings multiple is relatively high for the profit base.

Profit is still recovering from the 2024 peak, so the multiple is sensitive to the pace of recovery. The rise in 3Q 2026 operating profit alongside the drop in parent-company net profit is a variable in reading the multiple.

Dividend payouts are low, so most earnings are directed toward growth investment and capacity additions. Because the DIS contract runs until the end of April 2027, profit visibility beyond 2027 depends on contract renewal and growth in new product sales.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Quarterly recovery from DIS volumes

Revenue rose from the 4Q 2025 low to KRW 6.06 billion in 1Q 2026, KRW 7.64 billion in 2Q 2026 and KRW 7.87 billion in 3Q 2026. The company said the approximately KRW 21.2 billion DIS supply contract signed in May 2026 has been fully reflected from 2Q. Quarterly operating profit over the same period rose to KRW 1.11 billion, KRW 1.9 billion and KRW 1.99 billion.

Diversification through new High-k product lines

The company says revenue is now being generated from new High-k product lines, including molybdenum precursors and yttrium ligands. If these lines grow alongside the core CP and PCP ligands and DIS precursors, the impact of price cuts or volume swings on any single product could be spread out.

Compared with the High-k volume decline that weighed on 2025 results, the mix is shifting, which is the bullish point.

Medium-term options in hafnium localization and perovskite

Hafnium-based precursors have relied on imported core feedstock, and the company is pursuing full-process localization ahead of patent expiry at the end of 2026.

In perovskite, the company has signed a technology transfer contract with the Korea Research Institute of Chemical Technology, and NH Investment & Securities described it as securing a license to the underlying patent.

A securities analysis also says the Dangjin No. 3 plant is set to house hafnium production and dedicated perovskite equipment.

09

Bear factors

Structural causes of the 2025 earnings drop

Revenue fell 19.4% to KRW 20.2 billion in 2025, and operating profit fell 54.9% to KRW 4.57 billion. The company's disclosure cites lower High-k volumes, lower selling prices for key products and higher fixed costs from the No. 2 plant expansion.

Operating margin dropped from 40.5% to 22.6%, a year in which pricing and fixed costs weighed on results at the same time.

Sharp drop in 3Q parent-company net profit

Parent-company net profit was KRW 709 million in 3Q 2026, down 62.0% quarter on quarter and 54.8% year on year. Operating profit in the same quarter rose to KRW 1.99 billion.

Because the two lines moved in opposite directions, the next regular report needs to show how non-operating items and income tax moved between operating profit and parent-company net profit.

Customer concentration and limited investor relations

At the 2025 listing, about 90% of revenue was concentrated in one customer, which was classified as a risk. An April 2026 media report said the company had held only one investor relations event since listing.

With new-material commercialization expected around 2028, near-term results will continue to rely on the continuity of contracts with a small number of customers.

10

Risk factors

Customer concentration and contract renewal

The DIS supply contract ends on April 30, 2027. If customer concentration remains, changes in contract terms or volume would affect total revenue. About 90% concentration was already flagged as a risk at listing.

Whether expansion to Taiwan and mainland China customers can diversify that exposure is a matter to check in disclosures and investor materials.

Investment burden and fixed costs

The Dangjin No. 3 plant and infrastructure expansion at the No. 2 plant are underway, with investment completion reportedly targeted for 3Q 2027. In 2025, higher headcount and fixed costs after the No. 2 plant expansion were cited as a burden on results. If utilization fails to keep pace with supply growth, investment costs could again weigh on profit.

New-material commercialization and patent expiry

Patents related to hafnium-based precursors expire at the end of 2026, so the competitive landscape could shift afterward. The company expects perovskite R&D to be completed in 2028, which means revenue contribution from new materials could slip beyond that point. If commercialization is delayed while R&D costs continue to be expensed, profitability pressure may persist.

11

What to watch next

  1. Late December 2026

    The expiry of patents related to hafnium-based precursors. Checkpoints are whether localized full-process products move into mass production and whether customers adopt them.

  2. Around early February 2027

    The timing of the preliminary 4Q 2026 and full-year 2026 results. Last year's full-year results were disclosed on February 9, 2026. Checkpoints are whether 4Q operating profit holds near the 3Q level and how the full-year operating margin changes.

  3. End of March 2027

    The filing deadline for the 2026 annual business report. Checkpoints include how the gap between full-year operating profit and parent-company net profit arose from non-operating items and income tax.

  4. April 30, 2027

    The end date of the DIS supply contract. Whether a follow-on contract is signed, and on what terms, will shape revenue visibility from 2027 onward.

  5. 3Q 2027

    The targeted completion of investment at the Dangjin No. 3 plant, per an April 2026 media report. Checkpoints are the start of operations and whether hafnium and perovskite production equipment is installed.

12

Overall view

LK Chem makes ligands and precursors used in semiconductor deposition. In 2025, lower selling prices and higher fixed costs cut profit sharply.

In 2026, the DIS supply contract of about KRW 21.2 billion signed in May has been reflected in results, and revenue and operating profit rose for three consecutive quarters from 1Q to 3Q.

However, parent-company net profit fell 62.0% quarter on quarter to KRW 709 million in 3Q 2026, so the rise in operating profit did not carry through to parent-company profit.

Bullish factors are the recovery in DIS volumes, revenue from new High-k product lines, and medium-term options in hafnium localization and perovskite.

Bearish factors are concentration in a single customer, the possibility that the price and volume issues behind the 2025 drop recur, and uncertainty over when new materials will be commercialized.

The next checkpoints are the hafnium patent expiry at the end of 2026, the preliminary full-year 2026 results and annual business report, and the end of the DIS contract on April 30, 2027. This report is for information only and does not include a buy or sell opinion or a target price.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. newstown.co.kr
  2. newspim.com
  3. marketin.edaily.co.kr
  4. m.news.nate.com
  5. newstopkorea.com
  6. m.news.nate.com
  7. newspim.com
  8. newspim.com
  9. m.joseilbo.com
  10. thebell.co.kr
  11. m.news.nate.com
  12. youtube.com
  13. m.news.nate.com
  14. newspim.com
  15. edaily.co.kr

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis